Company intelligence / Profile preview

Precision BioPartners

Durham, North Carolina, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

PBGENE-HBV, Precision’s lead wholly owned in vivo gene editing program targeting chronic hepatitis B, has received FDA Fast Track designation. Initial safety and antiviral activity have been observed in the ongoing global Phase 1 ELIMINATE-B trial; further data from multiple dose cohorts are expected throughout 2025. The ARCUS platform enables precise gene knockout, insertion, or repair.

Therapeutic areas: Infectious Diseases
Modalities: Gene therapyGenome editingLipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

Eli Lilly (in vivo gene editing for up to six targets including Duchenne muscular dystrophy)Tiziana Life Sciences (exploring use of foralumab to aid CAR-T cell therapies)iECURE (liver disease candidates using ARCUS technology)Acuitas Therapeutics (provides lipid nanoparticle technology for PBGENE-HBV)

Beyond the preview

Go deeper on Precision BioPartners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision BioPartners.

Explore the full profile